Director Laura Oliphant of Aehr Test Systems (NASDAQ:AEHR) executed a sale of 1,716 shares of the companys common stock on April 16, 2026, at $81.54 per share, producing total gross proceeds of $139,922. The disposition was disclosed in a Form 4 filed with the Securities and Exchange Commission. Following the transaction, Oliphant directly holds 16,716 shares, a total that includes unvested restricted stock units.
At the time of reporting, Aehr Test Systems shares were trading at $83.86 and the company carried a market capitalization of $2.63 billion. The stock has experienced substantial appreciation over the past year, posting a return of 937 percent. Independent analysis from InvestingPro included in public materials characterizes the stock as appearing overvalued at current levels, while also noting the companys strong liquidity profile, with a current ratio of 10.97. InvestingPro highlights further valuation details and an additional set of ProTips in its Pro Research Report.
Financial and operational updates reported by the company paint a mixed picture. Aehr announced a record production order valued at $41 million from a hyperscale customer for package-level burn-in of custom AI processor ASICs. The award, the largest in the companys history, comprises Sonoma high-power package-level test and burn-in systems and is scheduled for delivery beginning in fiscal 2027.
On the quarterly front, Aehr Test Systems posted third-quarter fiscal 2026 results showing an earnings loss per share of $0.05, which was narrower than the forecasted loss of $0.07. Revenue for the quarter totaled $10.3 million, falling short of the expected $10.8 million. Despite the slight revenue miss, the company reported record quarterly bookings of $37.2 million, contributing to an effective backlog that exceeded $50 million at quarter end.
Market analysts have adjusted their price targets in response to these developments. Freedom Broker lifted its target to $61 while retaining a Hold rating. Lake Street increased its price objective to $56 and maintained a Buy rating, each firm citing strong bookings momentum as a driver for their revisions. These analyst actions underscore investor attention to the companys booking trends and backlog even as revenue performance marginally missed estimates.
From a profitability standpoint, Aehr remains unprofitable on a trailing twelve-month basis, with earnings per share of negative $0.38. The reported director sale, the sizable hyperscale order, quarterly results and analyst target changes were all disclosed publicly through company releases and filing channels.
Details on the insider sale and the companys financial metrics are sourced from the Form 4 filing and the companys reported quarterly disclosures. Additional valuation commentary and Pro Research materials are available through InvestingPro as noted in public summaries.